Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial
- Registration Number
- NCT00370851
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
In this study we intend to evaluate the outcome of intravitreal avastin on improving the visual acuity and macular edema and late complications of BRVO like NVD and NVE
- Detailed Description
After diabetic retinopathy, vein occlusion is the second most common retinovascular disease. According to BVO study the only effective management of it is macular photocoagulation for macular thickening that persist after 3 months.But we may miss a golden time which resulted to photoreceptor degeneration due to macular edema during this period. VEGF inhibitors newly have been shown that may be effective on a wide range of retinovascular diseases that resulted to macular edema or new vessels formation. In this study we aim to show the outcomes of one of this VEGF inhibitors (bevacizumab) on complications of BRVO in a sham controlled clinical trial.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 82
- patients with acute BRVO with less than three month duration
- vision less than 20/320 and vison more than 20/50
- duration more than 3 months
- history of glaucoma and diabetic retinopathy
- any media opacity that prevent funduscopy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Avastin (Bevacizumab) Intravitreal injection of Avastin 2 Avastin (Bevacizumab) -
- Primary Outcome Measures
Name Time Method Best corrected visual acuity At 12 week Macular thickness by OCT At 12 week
- Secondary Outcome Measures
Name Time Method Need for macular photocuagulation At 12th week Incidence of new vessel formation At 12th week
Trial Locations
- Locations (1)
Siamak Moradian, MD
🇮🇷Tehran, Iran, Islamic Republic of